Moffitt Cancer Center: New Drug Combination Shows Promising Activity in Non-Small Cell Lung Cancer Patients
August 27, 2019
August 27, 2019
TAMPA, Florida, Aug. 27 -- Moffitt Cancer Center issued the following news release:
Patients with non-small cell lung cancer (NSCLC) now have more improved treatment options compared to standard of care with the addition of several new agents called immune-checkpoint inhibitors (ICI). Despite these changes, many patients still develop progressive disease after ICI treatment. In a new study published in Clinical Cancer Research, Moffitt Cancer Center researchers describe promising re . . .
Patients with non-small cell lung cancer (NSCLC) now have more improved treatment options compared to standard of care with the addition of several new agents called immune-checkpoint inhibitors (ICI). Despite these changes, many patients still develop progressive disease after ICI treatment. In a new study published in Clinical Cancer Research, Moffitt Cancer Center researchers describe promising re . . .